Pharmacokinetic Modulation of Plasma 5-fluorouracil Concentrations to Potentiate the Antitumor Activity of Continuous Venous Infusion of 5-fluorouracil

Overview

Journal Jpn J Cancer Res

Specialty Oncology

Date 1989 Jun 1

PMID 2503471

Authors

S Fujii

M Fukushima

Y Shimamoto

T Shirasaka

Affiliations

Soon will be listed here.

Abstract

Methods for pharmacokinetic modulation of the plasma 5-fluorouracil (5-FU) level to increase antitumor activity during continuous venous infusion (CVI) of low doses of 5-FU were examined in Yoshida sarcoma-bearing rats. These methods were additional infusion of 5-FU for a short period (4 h) or oral administration of UFT or Tegafur during long-term CVI of 5-FU that alone gave a plasma 5-FU level of about 50 ng/ml. The antitumor effect on Yoshida sarcoma was markedly potentiated when an additive dose of 5-FU combined with 3-cyano-2,6-dihydroxypyridine (CNDP), a potent inhibitor of 5-FU degradation, giving a plasma level of about 500 ng/ml, was infused for 4 h. A similar increase in the antitumor effect was observed with oral administration of a conventional dose of UFT during CVI of 5-FU without CNDP, giving a plasma level of 30 to 60 ng/ml. These results suggest that the antitumor effect of CVI of 5-FU can be potentiated by pharmacokinetic modulation of the 5-FU concentration in the blood.

References

Tatsumi K, Fukushima M, Shirasaka T, Fujii S . Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res. 1987; 78(7):748-55. View

Lokich J, Fine N, Perri J, Bothe Jr A . Protracted ambulatory venous infusion of 5-fluorouracil. Am J Clin Oncol. 1983; 6(1):103-7. View

Fox R, Woods R, Tattersall M, Piper A, Sampson D . Allopurinol modulation of fluorouracil toxicity. Cancer Chemother Pharmacol. 1981; 5(3):151-5. DOI: 10.1007/BF00258472. View

Kanzawa F, Hoshi A, KURETANI K . Influence of duration of exposure to 5-fluorouracil on antiproliferating activity against cultured murine lymphoma cells. Br J Cancer. 1981; 44(5):757-9. PMC: 2010835. DOI: 10.1038/bjc.1981.265. View

Boublil J, Milano G, Khater R, Bourry J, Thyss A, Bruneton J . Continuous 5-day regional chemotherapy by 5-fluorouracil in colon carcinoma: pharmacokinetic evaluation. Br J Cancer. 1985; 52(1):15-20. PMC: 1977180. DOI: 10.1038/bjc.1985.142. View

Erlichman C, Fine S, Elhakim T . Plasma pharmacokinetics of 5-FU given by continuous infusion with allopurinol. Cancer Treat Rep. 1986; 70(7):903-4. View

Petit E, Milano G, Levi F, Thyss A, Bailleul F, Schneider M . Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients. Cancer Res. 1988; 48(6):1676-9. View

Caballero G, AUSMAN R, Quebbeman E . Long-term, ambulatory, continuous IV infusion of 5-FU for the treatment of advanced adenocarcinomas. Cancer Treat Rep. 1985; 69(1):13-5. View

Fujii S, Shimamoto Y, Ohshimo H, Imaoka T, Motoyama M, Fukushima M . Effects of the plasma concentration of 5-fluorouracil and the duration of continuous venous infusion of 5-fluorouracil with an inhibitor of 5-fluorouracil degradation on Yoshida sarcomas in rats. Jpn J Cancer Res. 1989; 80(2):167-72. PMC: 5917696. DOI: 10.1111/j.1349-7006.1989.tb02285.x. View

10.

Sullivan R, Young C, Miller E, GLATSTEIN N, Clarkson B, Burchenal J . The clinical effects of the continuous administration of fluorinated pyrimidines (5-fluorouracil and 5-fluoro-2'-deoxyuridine). Cancer Chemother Rep. 1960; 8:77-83. View

11.

Byfield J, FRANKEL S, Hornbeck C, Sharp T, Callipari F, Floyd R . Phase I and pharmacologic study of 72-hour infused 5-fluorouracil in man. Am J Clin Oncol. 1985; 8(5):429-40. DOI: 10.1097/00000421-198510000-00017. View

12.

Byfield J, Ward J, Sharp T . Time-dose relationships for 5-fluorouracil cytotoxicity against human epithelial cancer cells in vitro. Cancer Res. 1982; 42(11):4413-20. View

13.

Spicer D, Ardalan B, Daniels J, SILBERMAN H, Johnson K . Reevaluation of the maximum tolerated dose of continuous venous infusion of 5-fluorouracil with pharmacokinetics. Cancer Res. 1988; 48(2):459-61. View

14.

Ikenaka K, Shirasaka T, Kitano S, Fujii S . Effect of uracil on metabolism of 5-fluorouracil in vitro. Gan. 1979; 70(3):353-9. View

15.

Seifert P, Baker L, Reed M, VAITKEVICIUS V . Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer. 1975; 36(1):123-8. DOI: 10.1002/1097-0142(197507)36:1<123::aid-cncr2820360108>3.0.co;2-c. View

16.

Shah A, Macdonald W, Goldie J, Gudauskas G, Brisebois B . 5-FU infusion in advanced colorectal cancer: a comparison of three dose schedules. Cancer Treat Rep. 1985; 69(7-8):739-42. View

17.

Drewinko B, Yang L . Cellular basis for the inefficacy of 5-FU in human colon carcinoma. Cancer Treat Rep. 1985; 69(12):1391-8. View

18.

Tane S, Ogawa Y, Kido Y, Ogawa M, Shiozaki H, Miyamoto T . [Continuous venous infusion of 5-fluorouracil (5-FU) under total parenteral nutrition (TPN) in advanced gastric cancer]. Gan To Kagaku Ryoho. 1985; 12(12):2322-6. View

19.

Link K, Aigner K, Peschau K, Warthona M, SCHWEMMLE K, Danenberg P . Concentration and time dependence of the toxicity of fluorinated pyrimidines to HT 29 colorectal carcinoma cells. Cancer Chemother Pharmacol. 1988; 22(1):58-62. DOI: 10.1007/BF00254182. View